LexBlog IP

DECEMBER 13, 2023

The post Janssen and Samsung Bioepis Settle STELARA (Ustekinumab) Litigation appeared first on Big Molecule Watch.

Litigation 52

Litigation Settlement Licensing Marketing 52

JD Supra Law

DECEMBER 13, 2023

Samsung Bioepis recently reported that it has signed a settlement and license agreement with Johnson & Johnson (“J&J”) in the United States relating to SB17, Samsung Bioepis’s ustekinumab biosimilar to J&J’s STELARA®. If SB17 is approved by the FDA, the license period in the United States will begin on February 22, 2025.

Litigation 69

Litigation Settlement Licensing Reporting 69

LexBlog IP

MARCH 6, 2024

announced it has signed a settlement agreement with Bayer Inc. The settlement resolves multiple patent infringement proceedings in the Federal Court of Canada. Under the agreement, Biocon can launch YESAFILI in Canada no later than July 1, 2025. On March 4, Biocon Biologics Ltd. and Regeneron Pharmaceuticals, Inc.

Marketing 52

Marketing Marketing Settlement Litigation 52

JD Supra Law

AUGUST 3, 2023

Welcome to our quarterly update relating to biologics and biosimilars, including post-grant and patent litigation challenges to blockbuster biologics. Notably, since our last update, Janssen and Amgen reached a settlement allowing for the launch of Amgen’s biosimilar to Stelara no later than January 1, 2025. By: Morgan Lewis

Settlement 52

Settlement Litigation Patent 52

SpicyIP

MARCH 15, 2024

Since parties could not arrive at a settlement, ID initiated patent infringement proceedings against the defendants in UK, Germany and India. If the trial spills over to 2025, the defendants will have to bear the cost for that as well. The parties commenced joint negotiations in 2021.

Patent Infringement 59

Patent Infringement Settlement Patent Licensing 59

LexBlog IP

NOVEMBER 5, 2023

As we covered previously , Janssen and Amgen settled their BPCIA litigation regarding Amgen’s ustekinumab biosimilar product in May 2023. ” (CMS’s position on this has been challenged in pending litigation.) WEZLANA is the first product to be approved as a biosimilar to STELARA.

Marketing 40

Marketing Marketing Government Litigation 40

The IPKat

FEBRUARY 29, 2024

This New York action has been stayed pending resolution of the English litigation. It is likely therefore that it will stand to be determined by a High Court judge some time in 2025. Are you experienced” The most recent hearing in the English proceedings was to consider Sony’s application for summary judgment (i.e.

Copyright 109

Copyright Reporting Contracts Settlement 109